Virax Biolabs Group Ltd
corporate_fare Company Profile
Virax Biolabs Group Ltd (NASDAQ:VRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for VRAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for VRAX spans 6-K, F-3, 20-F.
Recent high-impact activity:
- Virax Sets Nov 27 Vote on 1-for-4 Reverse Split and 4x Authorized Share Increase
- Shareholders Clear 500M Share Increase, Reject Amended Articles
- Virax Biolabs Proposes 250-Fold Jump in Authorized Shares to 500 Million
- Virax Registers Resale of 1.68M Shares Underlying Warrants — But Lacks Authorized Shares to Issue Them
- Virax Biolabs CEO Touts Nasdaq Compliance, Cash Runway, and Fosun Deal in Letter to Shareholders
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 6,682 shares in VRAX as of the October 30, 2026 settlement, a 25.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 53.1% of VRAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for VRAX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-04.
Resale Registration for 1.68M Shares · Authorized Share Shortfall
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
VRAX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.